A new drug built in a Texas lab has done something cancer researchers have chased for decades: it made resistant tumor cells vulnerable to treatment again.
Quick Take
- Baylor College of Medicine researchers created an experimental drug called CS18 that weakens the defenses cancer cells use to survive treatment.
- CS18 restored sensitivity to a lung cancer drug called osimertinib in cells that had become resistant to it.
- In animal tests, CS18 slowed tumor growth without causing major weight loss or other signs of toxicity.
- The findings appeared in the journal Science Advances, but the drug still has a long road before it could reach human patients.
How CS18 Attacks Cancer’s Survival Toolkit
Cancer cells are stubborn. Give them a drug, and many find a workaround to keep growing. Baylor College of Medicine researchers say CS18 disrupts that workaround directly. The drug targets a protein called TopBP1, short for topoisomerase IIβ-binding protein 1, which cancer cells lean on to repair damage and dodge treatment.
Blocking TopBP1 does not just slow the cancer cell down. It appears to strip away several defense mechanisms at once, according to the Baylor team, making it harder for the tumor to recover once treatment starts working against it.
That matters because drug resistance is often the real reason cancer treatment eventually stops working. A chemotherapy or targeted drug can shrink a tumor for months or years, only for the cancer to mutate and grow back immune to it. CS18 aims at that exact failure point instead of just adding another attack from a new angle.
Lung Cancer Cells Regained Their Sensitivity to Treatment
The most striking result came in lung cancer cells that had already become resistant to osimertinib, a widely used targeted therapy. Researchers found that adding CS18 restored the cancer cells’ sensitivity to osimertinib, increasing cancer cell death rather than letting the tumor cells shrug off the drug.
That kind of reversal is rare in cancer research. Most resistance is treated as a one-way street once it develops. If CS18 can genuinely turn drug-resistant cells back into drug-sensitive ones, it could extend the usefulness of therapies doctors already prescribe instead of forcing patients to start over with something new.
Animal studies backed up the lab results. Mice treated with CS18 showed significantly slower tumor growth, and researchers reported no major weight loss or other clear toxicity signs during testing. That safety signal, while early, is exactly what researchers look for before considering the next stage of testing.
Why Most Promising Cancer Drugs Never Reach Patients
CS18’s early results are real and worth attention. They are also a first step in a process that rarely ends in a pharmacy shelf. Oncology drugs fail in clinical development more often than drugs for almost any other disease, with failure rates approaching 90 percent after promising lab work.
Part of the problem is translation. Studies tracking cancer drugs from animal testing to human trials have found that fewer than 8 percent of those candidates go on to succeed in patients, even after strong results in mice. Oncology chemotherapies specifically carry the highest drug failure rate of any drug class researchers track.
New drug CS18 shows promise against cancer treatment resistance
Experimental drug CS18 reversed therapy resistance in lung cancer cells and slowed tumor growth in animal models.#Science #Health #Cancer
Read more: https://t.co/AlxuHihOCv— Minute Brief (@theminutebrief) September 23, 2026
None of that erases what CS18 has shown so far. It means the compound now enters a demanding pipeline where most candidates, even good ones, eventually stall. The next steps for the Baylor team would likely involve expanded safety testing and combination studies before any human trial could begin.
For patients and families watching cancer research headlines, the lesson is not to lose hope but to keep expectations honest. A drug that restores sensitivity in resistant lung cancer cells and slows tumors in mice is genuinely encouraging science. It is also, for now, exactly that: encouraging science, not a treatment sitting in a doctor’s office. The distance between those two things is where most cancer breakthroughs quietly disappear, and where CS18 will now be tested.
Sources:
sciencedaily.com, linkedin.com, blogs.bcm.edu, worldpharmanews.com, bioengineer.org
